Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
SFST, VLTO, CLIR, More
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Steel Dynamics (STLD) Tops Q1 EPS by 16c
- Veritex Holdings (VBTX) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
